Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion

Objectives To determine the relationship between treatment frequency with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes in eyes with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO) in US clinical practice. Methods Study...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2023-11, Vol.37 (16), p.3423-3428
Main Authors: Modi, Yasha S., Goduni, Lediana, Moini, Hadi, Gibson, Andrea, Boucher, Nick, Lucas, Genevieve, Dhoot, Dilsher S.
Format: Article
Language:English
Subjects:
692/699/3161/3175
692/700/565/1436
Angiogenesis Inhibitors - therapeutic use
Bevacizumab - therapeutic use
Clinical medicine
Edema
Endothelial Growth Factors - therapeutic use
Humans
Intravitreal Injections
Laboratory Medicine
Macular Edema - drug therapy
Macular Edema - etiology
Medical records
Medicine
Medicine & Public Health
Ophthalmology
Patients
Pharmaceutical Sciences/Technology
Ranibizumab - therapeutic use
Retinal Vein Occlusion - complications
Retinal Vein Occlusion - drug therapy
Retrospective Studies
Surgery
Surgical Oncology
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - therapeutic use
Visual acuity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To determine the relationship between treatment frequency with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes in eyes with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO) in US clinical practice. Methods Study eyes that initiated anti-VEGF injections between January 2012 and May 2016 were followed for ≥1 year in a retrospective analysis of medical records (Vestrum Health database). Eyes were analysed in 2 cohorts by treatment duration (years 1 and 2) and then in 2 subcohorts by injection frequency (≤6 or ≥7 injections/year). Results Among 3099 eyes with MO secondary to BRVO, 1197 (38.6%) received ≤6 injections (mean injections, 4.6; baseline mean VA, 53 letters) and 1902 (61.4%) received ≥7 injections through 1 year (mean injections, 8.8; baseline mean VA, 52 letters). At year 1, mean VA gain from baseline was 10.4 versus 13.9 letters in eyes receiving ≤6 versus ≥7 injections ( p  
ISSN:0950-222X
1476-5454
DOI:10.1038/s41433-023-02527-7